Rezultati pretraživanja
  1. 3. velj

    What a week! Bio-Link was delighted to represent our client, , at . We travelled over 31 km (generally on foot) around San Francisco, meeting with leading pharma executives, sharing the latest exciting data and future strategy for the development of

  2. 13. sij

    We are delighted to be at . This is a great opportunity to update on latest developments. Xanamem has been demonstrated to be an efficacious, brain penetrant & appropriately safe oral drug, with clinical results in line with its intended mechanism of action.

  3. 10. sij

    & Week provides with an excellent opportunity to update the pharmaceutical industry & major global investors interested in Neuroscience on the compelling results achieved with XanaHES, & the expanded dataset generated during 2019.

  4. 31. lis 2019.

    Did you miss our presentation at ? Will Canty at speaks to to get an update on , the recent breakthrough results from the XanaHES trial and the exciting pathway forward

  5. 27. lis 2019.
  6. 23. lis 2019.

    Our 30 Sep 2019 quarter was particularly productive and Actinogen is delighted with the positive XanaHES results released earlier this month

  7. 3. lis 2019.

    has got to be the best stock of the week so far & maybe month unless another run happens. It went up 466.67% then dropped next day & its back up again today 23.68% The power of

  8. 29. lip 2019.

    Comprehensive suite of studies underway to optimise the future development strategy for

  9. 24. tra 2019.

    Interesting article. Could Actinogen Medical be developing as the next therapy to show benefits for patients?

  10. 15. tra 2019.

    Actinogen Medical CEO Bill Ketelbey highlighting the great progress and opportunities for !

  11. 26. ožu 2019.

    Congratulations @actinogenmedical - Further support for the safety of in the treatment of

  12. 11. pro 2018.

    . has completed the recruitment of participants for its Phase II clinical trial of for ’s disease. Results are expected in Q2 2019.

  13. 27. stu 2018.

    Find out more on XanADu, and in and other neurological diseases, with commentary from and the Xanamem Clinical Advisory Board. via

  14. 26. stu 2018.

    “Enrolment of the final patient into XanADu, Ph II of in , represents a major milestone for , as we now have certainty on the timeline to completion of the trial and reporting out of the results.”

  15. 25. stu 2018.

    A significant milestone achieved, has enrolled final patient into XanADu, its Ph II of in the treatment of patients with mild . Actinogen is on track to report out the results during 2Q CY19.

  16. 29. lis 2018.

    A great day so far at ! has just given a great presentation regarding and

  17. RT : September is World Alzheimer's & Dementia Awareness Month. Read more to find out why Actinogen's progress is good news for Alzheimer's patients.

  18. 20. ruj 2018.

    ⁩ speaks with Alan Kohler about Medical and , the novel treatment under development for treating Alzheimer’s Disease. A compelling investment oppprtunity

  19. 16. srp 2018.

    Actinogen Medical continues to make great progress with the development of  for the treatment of  disease. To learn more about this partnering opportunity go to: 

  20. 15. srp 2018.

    The momentum of XanADu continues to build! treatment. Learn more about partnering to develop and commercialise Xanamem

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.